<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00253630</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02843</org_study_id>
    <secondary_id>NCI-2012-02843</secondary_id>
    <secondary_id>PHII-63</secondary_id>
    <secondary_id>PHII-63</secondary_id>
    <secondary_id>6963</secondary_id>
    <secondary_id>N01CM17101</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>U01CA062505</secondary_id>
    <secondary_id>N01CM62209</secondary_id>
    <nct_id>NCT00253630</nct_id>
  </id_info>
  <brief_title>Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well vorinostat works in treating patients with relapsed
      or refractory indolent non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as
      vorinostat, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells
      by blocking some of the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the anti-tumor activity of SAHA (vorinostat) as assessed by the objective
      response rate, time to progression and survival in subjects with advanced lymphoma.

      II. To assess the toxicity profile of SAHA in this patient population. III. To perform
      correlative laboratory investigations to confirm modulation of chromatin acetylation as the
      biologic target and attempt to gain insight into the downstream molecular mechanisms involved
      in the induction of apoptosis mediated by SAHA.

      OUTLINE:

      Patients receive vorinostat orally (PO) twice daily (BID) on days 1-14. Treatment repeats
      every 21 days for up to 12 courses in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up every 3 months for 1 year and
      then every 6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Radiological assessment by CT and/or PET scan after every three cycles (every 3 months). Response assessed by the standard Cheson criteria (Cheson et al, J Clin Oncol 17:1244, 1999). Complete Remission (CR) - (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative (b) Variably FDG-avid or PET negative; regression to normal size on CT; Partial Remission (PR) - 50% or greater decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. Response Rate = CR + PR.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Grades 3 &amp; 4 adverse events definitely, probably or possibly related to treatment, graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Histone Acetylation by Immunohistochemistry (IHC)</measure>
    <time_frame>Baseline to up to day 14</time_frame>
    <description>Histone acetylation by IHC will be scored as -, +, ++, or +++, reflecting both the intensity of staining as well as the number of cells stained. Analysis will be descriptive, with the goal of describing baseline distributions and estimating the frequency and degree of changes from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Histone Acetylation by Western Blot (WB)</measure>
    <time_frame>Baseline to up to day 14</time_frame>
    <description>Histone acetylation by WB will be recorded as the ratio of acetylated histone (measured by photodensitometry) divided by the total histone (H3 or H4), in order to control for the amount of protein loaded. Analysis will be descriptive, with the goal of describing baseline distributions and estimating the frequency and degree of changes from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-Year Overall Survival</measure>
    <time_frame>Until Death from any cause, up to 2 years</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-Year Progression Free-Survival</measure>
    <time_frame>Until death or progression, up to 2 years</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier. Progression defined as any new lesion or increase by greater than 50% of previously involved sites from nadir.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue</condition>
  <condition>Nodal Marginal Zone Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 3 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (vorinostat)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (vorinostat)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (vorinostat)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>MSK-390</other_name>
    <other_name>SAHA</other_name>
    <other_name>Suberanilohydroxamic Acid</other_name>
    <other_name>Suberoylanilide Hydroxamic Acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed relapsed/refractory
             indolent Non-Hodgkin's lymphoma (Included in this category are relapsed/refractory
             follicular center lymphomas grade I, II, III, relapsed /refractory marginal zone
             B-cell lymphoma (nodal and extranodal), relapsed/refractory mantle cell lymphoma)

          -  Patients must have measurable disease by computed tomography (CT) scan. positron
             emission tomography (PET) scan evaluations are desirable but not mandatory, so that
             patients with negative PET scans but measurable disease by CT are eligible

          -  Patients may have had up to four prior chemotherapeutic regimens; steroids alone and
             local radiation do not count as regimens (radiotherapy must have been completed at
             least 14 days prior to starting SAHA); rituxan alone does not count as a regimen,
             however, Bexxar or Zevalin do; the most recent therapy must have failed to induce a
             complete response, or there must be disease progression or recurrence after the most
             recent therapy

          -  Patients may be enrolled who relapse after autologous stem cell transplant if they are
             at least three months after transplant, and after allogeneic transplant if they are at
             least six months post transplant; to be eligible after either type of transplant,
             patients must have achieved platelet counts greater than 100,000/mcL, and white blood
             cell (WBC) greater than 1,000/mcL at some point after their transplant, and should
             have no active related infections (i.e. fungal or viral); in the case of allogeneic
             transplant relapse, there should be no active acute graft versus host disease (GvHD)
             of any grade, and no chronic graft versus host disease other than mild skin, oral, or
             ocular GvHD not requiring systemic immunosuppression

          -  Life expectancy of greater than 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status #2 (Karnofsky &gt;= 60%)

          -  Absolute neutrophil count &gt;= 1,000/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Total bilirubin within normal institutional limits; patients with elevation of
             unconjugated bilirubin alone, as in Gilbert's Disease, are eligible

          -  Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate [SGPT]) =&lt; 2.5 x
             institutional upper limit of normal

          -  Creatinine up to and including 2 mg/dl

          -  Premenopausal women must have a negative serum pregnancy test prior to entry on this
             study; the effects of SAHA on the developing human fetus at the recommended
             therapeutic dose are unknown; women of child-bearing potential and men must agree to
             use adequate contraception (hormonal or barrier method of birth control; abstinence)
             prior to study entry and for the duration of study participation; should a woman
             become pregnant or suspect she is pregnant while participating in this study, she
             should inform her treating physician immediately

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have had chemotherapy within 4 weeks, rituximab within three months
             (unless there is evidence of progression) or radiotherapy within 2 weeks or those who
             have not recovered from adverse events due to agents administered more than 4 weeks
             earlier are excluded; this does not include use of steroids, which may continue until
             two days prior to enrollment; low dose chlorambucil should be stopped two weeks prior
             to beginning SAHA; valproic acid should be stopped at least two weeks prior to
             enrollment; nitrosoureas and mitomycin should be stopped 6 weeks prior to enrollment

          -  Patients may not be receiving any other investigational agents

          -  Patients with known brain metastases are excluded from this clinical trial unless the
             metastases are controlled after therapy and have not been treated with steroids within
             the past two months

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to SAHA

          -  There must be no plans for the patient to receive concurrent hormonal, biological or
             radiation therapy

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if
             the mother is treated with SAHA

          -  Human immunodeficiency virus (HIV)-positive patients receiving combination
             antiretroviral therapy are ineligible

          -  Patients with other active malignancies are ineligible for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Popplewell</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2005</study_first_submitted>
  <study_first_submitted_qc>November 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2005</study_first_posted>
  <results_first_submitted>December 20, 2017</results_first_submitted>
  <results_first_submitted_qc>February 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2018</results_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Vorinostat)</title>
          <description>Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Vorinostat: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two enrolled patients were ineligible due to diffuse B-cell lymphoma at start of treatment. Treatment was changed for these ineligible patients (within 2 months of enrollment) before a response evaluation. These patients were removed and are not included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Vorinostat)</title>
          <description>Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Vorinostat: Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" lower_limit="32" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Radiological assessment by CT and/or PET scan after every three cycles (every 3 months). Response assessed by the standard Cheson criteria (Cheson et al, J Clin Oncol 17:1244, 1999). Complete Remission (CR) - (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative (b) Variably FDG-avid or PET negative; regression to normal size on CT; Partial Remission (PR) - 50% or greater decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. Response Rate = CR + PR.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vorinostat)</title>
            <description>Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Vorinostat: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Radiological assessment by CT and/or PET scan after every three cycles (every 3 months). Response assessed by the standard Cheson criteria (Cheson et al, J Clin Oncol 17:1244, 1999). Complete Remission (CR) - (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative (b) Variably FDG-avid or PET negative; regression to normal size on CT; Partial Remission (PR) - 50% or greater decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. Response Rate = CR + PR.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="15" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Grades 3 &amp; 4 adverse events definitely, probably or possibly related to treatment, graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vorinostat)</title>
            <description>Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Vorinostat: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Grades 3 &amp; 4 adverse events definitely, probably or possibly related to treatment, graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ANC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection -Skin (cellulitis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes (total WBC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mucositis/stomatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombosis/thrombus/embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Histone Acetylation by Immunohistochemistry (IHC)</title>
        <description>Histone acetylation by IHC will be scored as –, +, ++, or +++, reflecting both the intensity of staining as well as the number of cells stained. Analysis will be descriptive, with the goal of describing baseline distributions and estimating the frequency and degree of changes from baseline.</description>
        <time_frame>Baseline to up to day 14</time_frame>
        <population>Immunohistochemistry data was not collected and is not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vorinostat)</title>
            <description>Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Vorinostat: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Histone Acetylation by Immunohistochemistry (IHC)</title>
          <description>Histone acetylation by IHC will be scored as –, +, ++, or +++, reflecting both the intensity of staining as well as the number of cells stained. Analysis will be descriptive, with the goal of describing baseline distributions and estimating the frequency and degree of changes from baseline.</description>
          <population>Immunohistochemistry data was not collected and is not available for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Histone Acetylation by Western Blot (WB)</title>
        <description>Histone acetylation by WB will be recorded as the ratio of acetylated histone (measured by photodensitometry) divided by the total histone (H3 or H4), in order to control for the amount of protein loaded. Analysis will be descriptive, with the goal of describing baseline distributions and estimating the frequency and degree of changes from baseline.</description>
        <time_frame>Baseline to up to day 14</time_frame>
        <population>Western Blot data was not collected and is not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vorinostat)</title>
            <description>Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Vorinostat: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Histone Acetylation by Western Blot (WB)</title>
          <description>Histone acetylation by WB will be recorded as the ratio of acetylated histone (measured by photodensitometry) divided by the total histone (H3 or H4), in order to control for the amount of protein loaded. Analysis will be descriptive, with the goal of describing baseline distributions and estimating the frequency and degree of changes from baseline.</description>
          <population>Western Blot data was not collected and is not available for analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-Year Overall Survival</title>
        <description>Estimated using the product-limit method of Kaplan and Meier.</description>
        <time_frame>Until Death from any cause, up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vorinostat)</title>
            <description>Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Vorinostat: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>2-Year Overall Survival</title>
          <description>Estimated using the product-limit method of Kaplan and Meier.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="64" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-Year Progression Free-Survival</title>
        <description>Estimated using the product-limit method of Kaplan and Meier. Progression defined as any new lesion or increase by greater than 50% of previously involved sites from nadir.</description>
        <time_frame>Until death or progression, up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Vorinostat)</title>
            <description>Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Vorinostat: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>2-Year Progression Free-Survival</title>
          <description>Estimated using the product-limit method of Kaplan and Meier. Progression defined as any new lesion or increase by greater than 50% of previously involved sites from nadir.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="24" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were collected over a period of 10 years, 8 months.</time_frame>
      <desc>&quot;Other Adverse Events&quot; include all events that were not severe adverse events regardless of grade or relation to treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Vorinostat)</title>
          <description>Patients receive vorinostat PO BID on days 1-14. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Vorinostat: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>meddra10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ear, nose and throat examination abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>meddra10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Hemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>External ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Ear, nose and throat examination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Esophageal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Intra-abdominal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Nausea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Proctoscopy abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Small intestinal mucositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Chills</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Gait abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Lip infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypercholesterolemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum magnesium increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Serum triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Joint disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Tumor pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Neurological disorder NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hemorrhage urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Kidney pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Protein urine positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Reproductive tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Vaginal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vaginal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vaginal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pharyngeal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="meddra9.0">Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Rash desquamating</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Skin induration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Skin ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Sweating</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title vocab="meddra9.0">Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Two enrolled patients were ineligible due to diffuse B-cell lymphoma at start of treatment. Their treatment was changed (within 2 months of enrollment) before a response evaluation. These patients were removed and are not included in the analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Frankel, Ph.D.</name_or_title>
      <organization>City of Hope</organization>
      <phone>626-359-8111 ext 65265</phone>
      <email>pfrankel@coh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

